Dr. Reddy’s laboratories said on Saturday that it has tied up with Glenmark Pharmaceuticals to acquire its selective anti-allergy brands in Russia, Ukraine, Kazakhstan and Uzbekistan.
The Hyderabad-based company has signed a deal with Glenmark with Momento Rino (for Russia, Kazakhstan and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspy and Glanspray Active (for the brand). Has made definite agreement. Dr. Reddy’s laboratories said in a statement, Ukraine) with the right to trademark, for dossiers and patent of territory.
The acquired brands represent two types of products – a combination of ametasone mono product and amazestone of amazelastine, indicated for the treatment of seasonal and perennial allergic rhinitis.
The company, however, did not disclose the financial details.
“The new brands are a great addition to our product portfolio in Russia, Ukraine, Kazakhstan and Uzbekistan which are important key markets for us. The most recently acquired brand, Momat Reino, has recently received OTC registration in Russia and it Will enable quick access. This product to patients, “Dr. CEO of Reddy’s Laboratories Branded Markets (India and Emerging Markets) said MV Ramna.
The acquired products will enhance the company’s strong presence in the anti-allergy segment in these countries, and will also be able to offer more comprehensive solutions to patients in the region, he said.
In a separate statement, Glenmark Pharmaceuticals Chief Commercial Officer Robert Crockart said: In line with our strategy to launch our global anti-allergy brand Ryallatis, in the markets of Russia and other CIS countries, we decided to brand the Momento Gino and its division Expansion done “
As the company awaits approval to launch Ryaltis in the Russian market, it looks forward to strengthening the respiratory franchise in the Russia / CIS region, he said.
“We are committed to respiration globally,” Crockart said.
(Only the headline and picture of this report have been reworked by Business Standard employees; the rest of the content is auto-generated from a syndicated feed.)